Drugs in America: Why price and transparency are hot-button issues

It’s not your imagination — drug prices in the U.S. are increasing, and it’s happening at an alarming rate. So what is causing this sudden change in cost? Although this is a multifaceted issue, physicians need to understand what factors are influencing this surge in price, and why transparency on the subject is crucial as policy continues to develop. Two sessions during the Summer Academy Meeting will address these key issues.

0717-Levitt

Jacob Levitt, MD

In his Friday, Aug. 21, Plenary address, “Derm Drugs: The Price is Too Darn High!” Jacob Levitt, MD, will discuss how evolving theories about market share, the influence of lawmakers, and government regulation have affected generic drug prices. Dr. Levitt will focus on topics such as potential flaws in pricing assumptions with respect to generic drugs and their impact on cost to consumers. He also will address the notion that generic drugs are always less expensive than their brand name equivalents.

Lebwohl

Mark Lebwohl, MD

Taking that discussion even further, AAD President Mark Lebwohl, MD, will lead “Dialogues on Drug Pricing and Transparency” (F010) from 3 to 5 p.m. Friday, Aug. 21. The session will feature a panel of experts from the pharmaceutical, biotechnological, and generic drug sectors of industry, as well as representatives of private payers, prescribers, and patient groups. Topics will include the role of medication costs in assessing treatment options and the benefits and challenges of price transparency. Panelists also will discuss the market system, present current economic data about research and development costs, and review relevant developments in federal and state policy.

Panelists in the session will be: Leah McCormack Howard, JD, vice president of government relations and advocacy for the National Psoriasis Foundation; Matt Eyles, executive vice president of policy and regulatory affairs for American’s Health Insurance Plans; Lori Reilly, executive vice president of policy and research for the Pharmaceutical Research and Manufacturers of America; and Everett Neville, senior vice president, supply chain, for Express Scripts.

The session is open to all registrants, so no ticket is required to attend. Session offers attendees 2 CME credits.

Return to index 

Top